GPP
Great Point Partners Portfolio holdings
AUM
$154M
This Quarter Return
+21.91%
1 Year Return
-2.36%
3 Year Return
+169.3%
5 Year Return
+292.82%
10 Year Return
+3,519.88%
AUM
$154M
AUM Growth
-$30.2M
(-16%)
Cap. Flow
-$43.8M
Cap. Flow
% of AUM
-28.45%
Top 10 Holdings %
Top 10 Hldgs %
66.56%
Holding
37
New
5
Increased
7
Reduced
9
Closed
10
Top Buys
| 1 |
Ionis Pharmaceuticals
IONS
|
$9.88M |
| 2 |
Rezolute
RZLT
|
$9.81M |
| 3 |
Legend Biotech
LEGN
|
$7.52M |
| 4 |
Akero Therapeutics
AKRO
|
$5.54M |
| 5 |
JBIO
Jade Biosciences, Inc. Common Stock
JBIO
|
$4.98M |
Top Sells
| 1 |
Akebia Therapeutics
AKBA
|
$10.9M |
| 2 |
Viridian Therapeutics
VRDN
|
$10.1M |
| 3 |
Merus
MRUS
|
$9.98M |
| 4 |
KalVista Pharmaceuticals
KALV
|
$7.81M |
| 5 |
Ascendis Pharma
ASND
|
$7.79M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
BBOT
26
BridgeBio Oncology Therapeutics, Inc. Common Stock
BBOT
$792M
| $312K | 0.2% |
29,381
-344,452
| -92% | -$3.66M |
|
|
27
Ascendis Pharma
ASND
$12.2B
| – | – |
-50,000
| Closed | -$7.79M |
|
|
AUTL
28
Autolus Therapeutics
AUTL
$375M
| – | – |
-2,728,910
| Closed | -$4.23M |
|
29
Beam Therapeutics
BEAM
$1.81B
| – | – |
-175,562
| Closed | -$3.43M |
|
30
Dianthus Therapeutics
DNTH
$769M
| – | – |
-275,000
| Closed | -$4.99M |
|
31
Dynavax Technologies
DVAX
$1.2B
| – | – |
-595,879
| Closed | -$7.73M |
|
|
MREO
32
Mereo BioPharma
MREO
$269M
| – | – |
-1,275,000
| Closed | -$2.87M |
|
|
33
Merus
MRUS
$4.99B
| – | – |
-237,156
| Closed | -$9.98M |
|
34
Vaxcyte
PCVX
$4.06B
| – | – |
-115,517
| Closed | -$4.36M |
|
35
Summit Therapeutics
SMMT
$17.2B
| – | – |
0
| – | – |
|
|
36
Viridian Therapeutics
VRDN
$1.56B
| – | – |
-750,000
| Closed | -$10.1M |
|
37
Voyager Therapeutics
VYGR
$201M
| – | – |
-626,275
| Closed | -$2.12M |
|